Apheresis for Lyme disease

What is H.E.L.P. apheresis?

Apheresis, from the Greek word for "to take away," refers to a class of medical procedures that separate and remove specific components from the blood. H.E.L.P. apheresis is a refined form developed in Germany that uses heparin precipitation to selectively filter pathological proteins while returning the cleaned blood to the patient.

The procedure was originally developed for patients with severe hyperlipidemia and cardiovascular disease. Over the past two decades, its application has expanded to include conditions characterized by high levels of circulating inflammatory mediators, including chronic Lyme disease.

During a H.E.L.P. apheresis session, blood is drawn from a peripheral vein, separated into plasma and cellular components, and the plasma is passed through a precipitation and filtration system. This system selectively removes:

• LDL cholesterol and lipoprotein(a) — which contribute to vascular inflammation and microcirculatory impairment
• Fibrinogen — elevated levels increase blood viscosity and impair capillary blood flow, contributing to fatigue and cognitive symptoms
• C-reactive protein (CRP) and other inflammatory markers — which reflect and drive systemic inflammation
• Circulating immune complexes — aggregates of antibodies and antigens that deposit in tissues and provoke ongoing inflammation
• Pro-inflammatory cytokines — signaling molecules that perpetuate the chronic inflammatory state

The cleaned plasma is recombined with the cellular components and returned to the patient. The entire process typically takes 2–3 hours and is performed by trained medical staff in a hospital setting.

Why apheresis is relevant for chronic Lyme patients

In chronic Lyme disease, the persistent infection triggers an inflammatory response that can become self-sustaining. Even when bacterial load is reduced through antimicrobial therapy and hyperthermia, the inflammatory mediators already circulating in the bloodstream continue to drive symptoms.

This is one reason why some patients experience only partial improvement from antimicrobial treatment alone: the bacteria may be reduced, but the inflammatory damage continues.

Specific mechanisms relevant to Lyme patients include:

Immune complex deposition. Borrelia antigens bind with patient antibodies to form immune complexes. These complexes can deposit in joints, the nervous system, and blood vessel walls, causing localized inflammation and tissue damage. Apheresis physically removes these complexes from circulation.

Elevated fibrinogen and blood viscosity. Many chronic Lyme patients have elevated fibrinogen levels, which increase blood viscosity and impair microcirculation. This contributes directly to symptoms such as brain fog, fatigue, cold extremities, and exercise intolerance. Reducing fibrinogen through apheresis can produce rapid improvement in these symptoms.

Cytokine storm reduction. Chronic Borrelia infection elevates pro-inflammatory cytokines such as IL-6, TNF-alpha, and IL-1beta. These cytokines perpetuate fatigue, pain, cognitive dysfunction, and mood disturbances. Apheresis reduces circulating cytokine levels, sometimes producing noticeable improvement within hours of the first session.

Endotoxin clearance. When Borrelia organisms are killed by hyperthermia or antimicrobials, they release endotoxins (lipoproteins from their outer membrane). These endotoxins can trigger intense inflammatory reactions, sometimes called Herxheimer-like responses. Apheresis performed around hyperthermia sessions helps clear these endotoxins before they trigger severe reactions.

How apheresis complements hyperthermia

Apheresis and hyperthermia address different aspects of chronic Lyme disease and are most effective when used together:

Hyperthermia targets the infectious agent directly. By raising core temperature to levels where Borrelia becomes structurally unstable, it reduces bacterial load. It also enhances immune function and improves the penetration of concurrent antimicrobial agents.

Apheresis targets the inflammatory consequences of infection. By removing circulating inflammatory mediators, immune complexes, and bacterial endotoxins, it reduces the symptom burden and creates a cleaner internal environment for recovery.

When performed in sequence, the two modalities create a synergistic effect: hyperthermia kills bacteria and releases their contents into the bloodstream, and apheresis clears those contents before they can trigger severe inflammatory reactions. This allows patients to tolerate more intensive treatment with fewer Herxheimer-like flares.

The medical team at Klinik St. Georg coordinates the timing of apheresis sessions relative to hyperthermia based on each patient's inflammatory markers, treatment response, and clinical status.

The procedure: what to expect

If apheresis is included in your treatment plan, here is what the procedure involves:

Before the session. A venous access is established, typically in the arm. Baseline blood work is drawn to document your inflammatory markers, fibrinogen level, and other parameters before filtration. Your medical team reviews any relevant laboratory changes since your last session.

During the session. Blood is drawn through one line, separated, filtered, and returned through the same or a second line. You are seated or reclined comfortably throughout. The procedure is not painful, though some patients report mild sensations of warmth or coolness as the blood is processed and returned. Each session lasts approximately 2–3 hours. You are monitored throughout by trained nursing staff.

After the session. Post-procedure blood work is drawn to measure the reduction in inflammatory markers. Most patients can return to their hospital room and resume normal activity immediately. Some report feeling lighter, mentally clearer, or less fatigued within hours. Others notice improvement more gradually over the following days.

Number of sessions. The number of apheresis sessions in a treatment program varies. Most patients receive 1–3 sessions over their 2–3 week stay, strategically timed around hyperthermia treatments. The schedule is individualized based on your inflammatory burden and clinical response.

Who benefits most from apheresis

Apheresis is not automatically included in every patient's treatment plan. It is particularly beneficial for patients who present with:

• Elevated inflammatory markers — high CRP, elevated fibrinogen, abnormal erythrocyte sedimentation rate (ESR)
• Significant brain fog or cognitive symptoms — which often correlate with elevated fibrinogen and impaired microcirculation
• Cardiovascular symptoms — palpitations, chest tightness, or exercise intolerance related to inflammatory vascular changes
• History of severe Herxheimer reactions — where clearing endotoxins before they accumulate can reduce reaction severity
• Documented immune complex deposition — confirmed through laboratory testing or clinical presentation
• Incomplete response to antimicrobial therapy — suggesting that the inflammatory burden, not just the infection, is driving persistent symptoms

Your medical team assesses these factors during the diagnostic phase and recommends apheresis when the clinical picture supports it.

Safety and considerations

H.E.L.P. apheresis has been used in clinical practice for over 25 years and has a well-documented safety profile. The procedure takes place in a hospital setting with continuous monitoring.

Common, mild effects include temporary drops in blood pressure during the procedure (managed with fluid adjustment), mild fatigue afterward, and minor bruising at the venous access site. These typically resolve within hours.

Rare but documented risks include allergic reactions to heparin (screened for in advance), transient electrolyte shifts, and in very rare cases, catheter-related complications. All patients are screened for contraindications before the procedure is recommended.

Not appropriate for all patients. Apheresis may not be recommended for patients with severe anemia, active bleeding disorders, heparin allergies or heparin-induced thrombocytopenia, or certain cardiovascular conditions. These are assessed during the pre-treatment evaluation.

It is important to understand that apheresis addresses the inflammatory consequences of chronic Lyme disease, not the infection itself. It is most effective as part of a comprehensive protocol that also addresses the underlying infection through hyperthermia and antimicrobial therapy.